Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 111 to 120 of 220 total matches.
Carboplatin
The Medical Letter on Drugs and Therapeutics • Sep 08, 1989 (Issue 800)
and generally less toxic than cisplatin for initial
chemotherapy of ovarian cancer.
THE MEDICAL LETTER (ISSN ...
Carboplatin (Paraplatin - Bristol-Myers), a cytotoxic platinum-containing drug chemically related to cisplatin (Platinol), was recently approved by the US Food and Drug Administration (FDA) for palliative treatment of patients with recurrent ovarian cancer, including those previously treated with cisplatin.
Futibatinib (Lytgobi) for Cholangiocarcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
Canc Netw 2019;
17:302.
6. MA Lowery et al. Second-line chemotherapy in advanced
biliary cancers ...
The oral kinase inhibitor futibatinib (Lytgobi –
Taiho) has received accelerated approval from the
FDA for treatment of adults with previously treated,
unresectable, locally advanced or metastatic
intrahepatic cholangiocarcinoma with fibroblast
growth factor receptor 2 (FGFR2) fusions or other
rearrangements. Accelerated approval was based
on the overall response rate and duration of
response. Futibatinib is the second drug to be
approved for this indication; pemigatinib (Pemazyre)
was approved earlier.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e69-70 doi:10.58347/tml.2023.1674f | Show Introduction Hide Introduction
Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer
The Medical Letter on Drugs and Therapeutics • Nov 06, 2017 (Issue 1533)
or two
chemotherapy regimens for metastatic disease received
abemaciclib monotherapy. At 12 months ...
The FDA has approved abemaciclib (Verzenio – Lilly),
an oral cyclin-dependent kinase (CDK) 4/6 inhibitor,
for treatment of hormone receptor (HR)-positive,
human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Abemaciclib is the third CDK 4/6 inhibitor to be
approved in the US for this indication.
Rasburicase (Elitek) for Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002 (Issue 1143)
high risk, either from rapid turnover of the cancer or from the
first course of chemotherapy ...
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients.
Beta-Adrenergic Blockers and Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jan 23, 2012 (Issue 1382)
blocker at the start of neoadjuvant chemotherapy was
associated with a significant decrease in breast ...
Three retrospective studies have recently reported an
association between beta-blocker use and a reduction
in breast cancer metastasis and recurrence. No
prospective, randomized trials have been published.
In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
, followed by high-dose
chemotherapy and, in responders, autologous stem
cell transplantation). Event-free ...
The FDA has approved lisocabtagene maraleucel
(Breyanzi – BMS) for treatment of adults with large
B-cell lymphoma (LBCL), including diffuse large
B-cell lymphoma (DLBCL) not otherwise specified,
high-grade B-cell lymphoma, primary mediastinal
large B-cell lymphoma, or follicular lymphoma
grade 3B who have disease refractory to first-line
chemoimmunotherapy, relapsed within 12 months
of or after first-line chemoimmunotherapy, are not
eligible for hematopoietic stem cell transplantation
due to comorbidities or age, or have relapsed
or refractory disease after ≥2 lines of...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e104-5 doi:10.58347/tml.2023.1679f | Show Introduction Hide Introduction
Azacitidine (Vidaza) for Myelodysplastic Syndrome
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005 (Issue 1201)
chemotherapy regimens, such as cytarabine (Cytosar-U,
and others) plus the anthracycline doxorubicin ...
Azacitidine (Vidaza - Pharmion), a pyrimidine nucleoside analog of cytidine, is the first drug approved by the FDA for treatment of myelodysplastic syndrome (MDS). Azacitidine is incorporated into newly synthesized DNA and inhibits DNA methyltransferase. Hypomethylation of DNA can restore the normal expression of genes critical for cell differentiation.
Panitumumab (Vectibix) for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Apr 23, 2007 (Issue 1259)
that has progressed
despite standard chemotherapy. It is the second monoclonal antibody EGFR inhibitor to be approved ...
Panitumumab (Vectibix - Amgen), a fully human IgG2 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), has been approved by the FDA for treatment of patients with EGFR-expressing metastatic colorectal cancer that has progressed despite standard chemotherapy. It is the second monoclonal antibody EGFR inhibitor to be approved for metastatic colorectal cancer; cetuximab (Erbitux), a human-murine chimeric IgG1 monoclonal antibody, was approved in 2004.
Epirubicin for Adjuvant Therapy in Node-Positive Breast Cancer
The Medical Letter on Drugs and Therapeutics • Feb 07, 2000 (Issue 1071)
or other hepatic impairment.
CLINICAL TRIALS — Adjuvant chemotherapy regimens commonly used to treat breast ...
Epirubicin, an analog of doxorubicin that has been available in Europe and Canada for 15 years, has now been approved by the FDA for adjuvant use after resection of the primary tumor in breast cancer patients with axillary node involvement.
Adagrasib (Krazati) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
mutations whose
disease had progressed on or after platinum-based
chemotherapy and an immune checkpoint ...
Adagrasib (Krazati – Mirati Therapeutics), a RAS
GTPase family inhibitor, has received accelerated
approval from the FDA for oral treatment of KRAS
G12C-mutated locally advanced or metastatic non-small
cell lung cancer (NSCLC) in adults who received
at least one prior systemic therapy. Accelerated
approval was based on the objective response rate
and duration of response.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e17-8 doi:10.58347/tml.2023.1668f | Show Introduction Hide Introduction